Biotechnology and Synthetic Biology IP Toolkit: Sequences, Deposits, Scope, and Genetic Resources

By Casey Scott McKay · 2024-05-28

Biotechnology sits at the point where three doctrines are hardest: eligibility, because the invention often begins with something found in nature; written description and enablement, because the claim often covers a genus defined by function; and disclosure, because a living organism cannot be described adequately in words. This toolkit collects the analysis. It works through sequence and antibody claiming after the Supreme Court's enablement decision, the deposit system that substitutes a sample for a description, and the eligibility line between an isolated natural product and a markedly different construct. It then addresses the collaboration architecture the field runs on — material transfer agreements, sponsored research, and platform licensing — and the genetic resource provenance obligations that now reach patent filings. It closes on regulatory exclusivity, which frequently matters more than the patents.

IP and Technology > Patent Counseling Transactions | Toolkit | Published 28 May 2024 - Updated 29 October 2024 | Casey Scott McKay - marksy.us

Summary. Biotechnology sits where three doctrines are hardest: eligibility, because the invention often begins with something found in nature; written description and enablement, because the claim often covers a genus defined by function; and disclosure, because a living organism cannot be described adequately in words. This toolkit works through sequence and antibody claiming after the Supreme Court's enablement decision, the deposit system that substitutes a sample for a description, and the eligibility line between an isolated natural product and a markedly different construct. It addresses the collaboration architecture the field runs on, the genetic resource provenance obligations that now reach patent filings, and the regulatory exclusivity that frequently matters more than the patents.

Keywords: biotechnology IP toolkit · sequence claims · written description · enablement after Amgen · biological deposits · Budapest Treaty · section 101 natural products · method of treatment claims · synthetic biology · genetic resource provenance · Nagoya compliance · material transfer agreements · biosimilar exclusivity · research tools · CRISPR licensing

Start Here

Three questions decide a biotechnology patent, and they are asked in this order.

Is it eligible? The invention frequently begins with a molecule, a sequence, or an organism that exists in nature, and 35 U.S.C. § 101 excludes natural products and natural laws as such.

Is it described and enabled? The claim frequently covers a class defined by what its members do rather than by what they are, and 35 U.S.C. § 112 asks whether the specification shows possession of that class and permits a skilled artisan to make and use it.

And is the material available? A living organism, a cell line, a hybridoma, or a plasmid cannot be described in words with enough precision to enable, and the deposit system exists to close that gap.

Everything else in this toolkit follows from those three, plus two features specific to the field: it is intensely collaborative, so ownership is contractual before it is doctrinal; and it is regulated, so exclusivity comes from approval regimes as much as from patents.

Eligibility, and Where the Line Sits

Isolation is not enough. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), held that a naturally occurring DNA segment is a product of nature and not eligible merely because it has been isolated, while complementary DNA is eligible because it is not naturally occurring.

Markedly different characteristics is the test. A construct, a fusion, a codon-optimised sequence, a mutant with altered function, or an engineered organism is not a natural product, and the specification should make the differences explicit rather than assuming a reader will infer them.

Natural correlations are not eligible. Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012), invalidated claims reciting a natural relationship plus conventional steps, and diagnostic claiming has been shaped by that decision more than by any other.

The Alice framework applies. Alice Corp. v. CLS Bank International, 573 U.S. 208 (2014), supplies the two-step analysis, and the second step asks whether the claim adds significantly more than the ineligible concept plus conventional activity.

Method of treatment claims remain eligible, which is why the drafting response to a diagnostic correlation is frequently a treatment claim: administer a specific compound to a patient identified by the marker, at a specified dose, for a specified indication.

Detection methods survive where the technique is new, and fail where the claim is a natural correlation detected by conventional means.

Process claims to methods of making — fermentation, expression, purification — are generally eligible and are systematically underused.

And the practical drafting response is a layered claim set. Composition claims to the engineered entity; method of making claims; method of use and method of treatment claims; and formulation claims. A programme that files only on the molecule has one claim type and one eligibility exposure, and both are avoidable.

Sequence and Antibody Claiming After Amgen

The scope problem in biotechnology is that the useful claim is functional. An antibody that binds a target epitope and blocks a receptor is a class defined by behaviour, potentially containing millions of members, of which a laboratory has made a few dozen.

That claim is now very hard to sustain. Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), held that the enablement requirement of 35 U.S.C. § 112(a) obliges the specification to enable the full scope of a functionally defined genus, and that disclosing a roadmap or a screening method for finding further members is not enablement — it is an invitation to further experimentation.

Written description compounds it. The Federal Circuit's antibody jurisprudence had already required more than a description of the target: a genus of antibodies must be described by structure, or by a representative number of species with common structural features, and describing only what the antibodies do describes the problem rather than the solution.

The Wands factors from In re Wands, 858 F.2d 731 (Fed. Cir. 1988), structure the undue experimentation analysis, and biotechnology is the paradigm unpredictable art, which cuts consistently against breadth.

The drafting response is structural, not functional, wherever possible. Claim the specific sequences by identifier. Claim defined percentage identity ranges to a disclosed sequence, with the retained function recited as a limitation and with data across the range. Claim the specific complementarity determining regions of the antibodies actually made. Claim the epitope by residue where the binding data supports it.

And file a nested set. A broad functional claim, several intermediate structural genera clustered around the data, and species claims on every construct actually made and characterised. The broad claim is a negotiating position; the intermediate claims are the asset.

Sequence listing compliance is mechanical and unforgiving. The standard format is prescribed, non-compliance draws notices, and errors in identifiers propagate into the claims, where they cause construction problems years later.

Deposits, Which Substitute Material for Description

Where a biological material cannot be described adequately in words, and is not publicly available, a deposit under the Budapest Treaty in a recognised international depositary authority satisfies the enablement requirement for that material.

The mechanics matter and are frequently mishandled. The deposit should be made before or at filing where possible; the accession number must be recited in the specification; the depositor must satisfy the availability and replacement obligations; and the deposit must be maintained for the statutory period, with viability testing on record.

What needs depositing. Cell lines, hybridomas, seeds, microorganisms, plasmids in host strains, and any material whose reproduction from the written description would require undue experimentation.

What does not. Material genuinely available to the public from a recognised source, and material a skilled artisan could make from the sequence information disclosed — which, for many nucleic acids and proteins, is now most of them.

Foreign requirements differ. Some jurisdictions require the deposit before filing rather than before grant, and a deposit made after a foreign filing date can be fatal in those systems. Check the depositing deadline for every jurisdiction in the family before the priority application is filed, because it cannot be cured afterwards.

And record the availability terms. A deposit made under restrictions inconsistent with the depositary's rules is a deposit that may not satisfy the requirement, and the problem surfaces in litigation rather than in prosecution.

Collaboration Architecture

Biotechnology runs on collaboration, and ownership is decided by documents signed by scientists rather than by doctrine.

Material transfer agreements move biological material between institutions and impose downstream obligations that travel with everything derived from it. They are signed without review with striking regularity, and a compound five years into development frequently carries reach-through terms nobody has read since.

Read the reach-through provisions specifically. A right to a licence on any invention made using the material, an option on commercial rights, or a share of proceeds converts a routine sample transfer into an encumbrance on the resulting programme.

Sponsored research agreements with universities carry publication rights, institutional policies that override individual agreements, and government funding conditions where federal money is involved — including election of title, government licence rights, and manufacturing preferences.

Publication is the recurring novelty problem. A poster, a preprint, or a conference abstract is a disclosure, and 35 U.S.C. § 102 provides a one-year domestic grace period and none in most other jurisdictions. A filing calendar that does not track the academic collaborator's submission calendar loses foreign rights routinely.

Joint inventorship is determined by contribution to conception, not by contract, and 35 U.S.C. § 116 allows joint inventors who did not work together physically or contribute to every claim. Under 35 U.S.C. § 262 each joint owner may make, use, and sell without accounting to the others, which is almost never what the collaborators intend and is the default they receive if nothing is agreed.

Contract research organisations own what they create absent an assignment, and their personnel are the ones at the bench.

Platform licences — expression systems, vectors, cell lines, screening technologies, and editing tools — carry field limitations, reach-through royalties, and improvement grant-backs that stack. Model the stack before the programme commits, because a therapeutic carrying four platform royalties is a therapeutic with a margin problem nobody costed.

And research tool patents raise the question of whether a research exemption applies. The common law exemption in United States practice is very narrow; the statutory safe harbour of 35 U.S.C. § 271(e)(1) is broad but limited to uses reasonably related to submissions to a regulatory agency. Assume no general research exemption, and license accordingly.

Genetic Resources and Provenance

Where biological material came from is now a patent question, not only a compliance one.

Access and benefit sharing. National legislation implementing the Nagoya Protocol requires permits, prior informed consent, and mutually agreed terms for access to genetic resources and to traditional knowledge associated with them, and the obligation follows the resource rather than the researcher's nationality.

Disclosure of origin. The 2024 WIPO treaty on intellectual property, genetic resources, and associated traditional knowledge introduces a requirement that patent applicants disclose the country of origin or source where an invention is based on genetic resources, and the providing community where associated traditional knowledge is involved. Several jurisdictions already impose analogous requirements.

So the provenance file has to exist before the application is drafted. Country and location of collection, date, collector, permit, attached terms, consent obtained and from whom, whether traditional knowledge directed the selection, and the chain of custody through every institution that has held the material.

Build it at collection, because it is unreconstructable later and because unanswerable provenance is itself a finding in acquisition diligence.

Repository material carries its own terms. Culture collections, herbaria, and biobanks impose downstream conditions that survive transfer, and a strain obtained from a collection is not free of obligation merely because it was obtained lawfully.

And human biological material engages consent, privacy, and — in several regimes — specific research governance requirements that are separate from the intellectual property analysis and considerably less forgiving.

Synthetic Biology Specifics

Engineered organisms and constructs raise a distinctive set of questions.

Eligibility is easier, because an engineered organism is not a natural product and the markedly different characteristics test is satisfied by construction.

Enablement is harder, because a claim to an organism engineered to perform a function invites exactly the Amgen problem, and the answer is structural claiming: specified genetic modifications, specified regulatory elements, specified host strains.

Deposits are frequently required, because an engineered strain cannot be reproduced from a written description without the parent material.

Open source and standard parts are common in this field, with registries of standardised biological parts distributed under public licences whose terms reach derivative constructs — the same analysis as open source software, applied to DNA, and equally frequently ignored.

Biosecurity and dual use regimes constrain both the work and the publication, and sequence screening obligations at synthesis providers create a compliance layer with no intellectual property analogue.

Environmental release engages separate approval regimes, and the regulatory package is again the barrier to entry rather than the patent.

And the trade secret alternative is real. Strain engineering, fermentation conditions, and downstream processing frequently leave no signature in the product, which makes secrecy under 18 U.S.C. § 1839 a genuine alternative to a published sequence — and Kewanee Oil Co. v. Bicron Corp., 416 U.S. 470 (1974), confirms the choice is legitimate.

Regulatory Exclusivity, Which Often Matters More

A biological product's market protection frequently comes from the approval regime rather than from a patent.

Reference product exclusivity for biologics runs from first licensure and bars approval of a biosimilar for a defined period, independent of patent status.

Orphan designation carries its own market exclusivity for the designated indication.

Paediatric extensions add term to existing exclusivities in exchange for studies.

And patent term restoration under 35 U.S.C. § 156 compensates for regulatory review time, subject to the eligibility conditions and the single-patent limitation that make the election consequential.

The patent dance for biosimilars is a statutory information exchange leading to phased litigation, and the strategic decisions — which patents to list, whether to participate, and how to sequence — are made under a timetable that leaves little room for reconsideration.

Which means the intellectual property strategy has to be built with the regulatory strategy, not delivered to it. A portfolio optimised for patent term without regard to the exclusivity clock, or a term restoration election made without modelling the biosimilar entry date, is a portfolio built on half the problem.

Building the Programme

Run the provenance file from the first collection. It is a records discipline, it costs nothing contemporaneously, and it cannot be built afterwards.

Audit the inbound agreements before the programme commits. Material transfer terms, platform licences, sponsored research conditions, and government funding obligations, with the reach-through and royalty stack modelled.

Fix the publication calendar to the filing calendar, with a standing rule that nothing is submitted, posted, or presented before a priority application is on file.

Draft layered claim sets — composition, method of making, method of use, method of treatment, formulation — and resist the instinct to file only on the molecule.

Claim structurally. Sequences by identifier, identity ranges supported by data, complementarity determining regions as made, epitopes by residue where the data supports it.

Plan the deposits against every jurisdiction's deadline, before the priority filing.

Model the exclusivity clock alongside the patent term, and make the restoration election with the biosimilar entry date in front of you.

Assess detectability for process inventions, and choose secrecy where a patent would publish an unenforceable recipe.

And treat the collaboration documents as the ownership architecture they are, because in this field the assignment schedule is more often decisive than the claim set.

A Worked Example

A start-up develops an antibody against a target identified in an academic collaboration, using a commercial expression platform, with a hybridoma derived from material obtained under a material transfer agreement.

The provenance question comes first. Where did the immunogen and the source material come from, under what permit and what terms, and does any associated traditional knowledge feature? If the target was identified from a natural source in a Nagoya party state, the answer determines whether the programme is compliant and what must be disclosed in the application.

The inbound agreements come second. The expression platform licence carries a reach-through royalty and a field limitation; the material transfer agreement carries an option on inventions made using the material; and the sponsored research agreement gives the university a publication right and, if federal funding was involved, gives the government a licence. Three encumbrances, none of which the founders knew about.

The claiming comes third. After Amgen, a claim to all antibodies binding the epitope and blocking the receptor will not survive. The filing is structural: the specific antibodies made, their complementarity determining regions, an identity range supported by the panel data, and method of treatment claims for the indication.

The deposit comes fourth. The hybridoma must be deposited, with the accession number in the specification, before the deadlines in the jurisdictions of interest — which for some means before filing rather than before grant.

And the exclusivity comes fifth. Reference product exclusivity, orphan designation if the indication qualifies, and patent term restoration modelled against the expected biosimilar entry.

Five questions, one programme, and the one the founders asked about was the third.

Prosecution Practice

Restriction practice shapes the family. Composition, method of making, method of use, and method of treatment are routinely restricted into separate applications, and the divisional strategy should be planned at filing so the safe harbour against double patenting is preserved.

File early and continue. Biotechnology programmes generate data continuously and a continuation-in-part adding new sequences or new data receives the earlier priority date only for what the parent supported — so the calendar governs the scope more than the drafting does.

Use the interview. Written description and enablement rejections turn on what the specification actually shows and on how a skilled artisan would read it, and both are resolved far more efficiently in conversation than across three written rounds.

Prepare declarations properly. A declaration supporting unexpected results, or establishing that a skilled artisan could practise the full scope, must come from someone with the relevant expertise, must address the claimed scope rather than a preferred embodiment, and must be supported by data in the record.

Watch prosecution history estoppel. Narrowing a sequence identity range or removing a functional limitation surrenders equivalents under Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (2002), which in this field means the numerical boundaries become literal.

Keep the candour file. The duty under 37 C.F.R. § 1.56 reaches adverse data known to the applicant, and a programme that submits favourable panel results while withholding the failures is generating the fact pattern for an inequitable conduct allegation years later.

And check the sequence listing against the claims at every amendment, because identifier errors propagate silently and surface at claim construction.

Diagnostics, Which Remain the Hardest Case

Diagnostic claiming has been the most disrupted area of biotechnology patenting, and the practical guidance is narrow but real.

Do not claim the correlation. A claim reciting detection of a marker and a conclusion about a condition is the Mayo fact pattern.

Claim the method of treatment instead. Administering a specified agent, at a specified dose, to a patient identified by the marker, for a specified indication — a claim type that has consistently survived eligibility challenge.

Claim the detection technique where it is genuinely new. A novel assay, a novel probe, a novel sample preparation, or a novel instrument configuration is a technical contribution rather than a natural law.

Claim the composition of matter — the probe, the primer set, the engineered reagent — where it is not naturally occurring.

Consider trade secret and regulatory routes. A laboratory developed test operated in a single laboratory need not be published at all, and the regulatory pathway plus the accumulated clinical validation dataset frequently provides more durable protection than a patent would.

And model the exclusivity honestly. A diagnostics business whose entire position rests on a correlation claim is a business whose position may not exist, and the earlier that is said the better the alternatives look.

Freedom to Operate

Biotechnology freedom to operate is sequence searching plus platform mapping, and both are frequently skipped until a financing requires them.

Search by sequence, not by keyword. Identity searching across patent sequence databases is the only reliable method, and a text search will miss a claim reciting a sequence identifier that covers the candidate.

Map the platform stack. Expression systems, vectors, cell lines, purification methods, screening technologies, editing tools, delivery systems, and analytical methods each may be patented and each may require a licence. The stack is where the exposure actually sits, and it is rarely surfaced by a search focused on the therapeutic itself.

Assess the safe harbour. 35 U.S.C. § 271(e)(1) exempts uses reasonably related to the development and submission of information under a federal regulatory law, and it is broad — but it does not cover commercial manufacture, and it does not cover research tools used outside that purpose in every court's view.

Assess validity where coverage is found, because after Amgen a functionally defined genus claim covering a candidate never described is precisely the claim most vulnerable under section 112.

Consider design-around at the sequence level, which is frequently available: a modification outside a claimed identity range, a different expression system, a different delivery vehicle.

Document the analysis with counsel so it supports the good faith position on willfulness, and re-run it at each development milestone and again before commercial manufacture — because the process, not the molecule, is where the platform claims bite.

Scale and Cadence

An academic spin-out needs the inbound agreements audited, the publication calendar fixed to the filing calendar, inventor assignments in place, and a provenance file if any biological material came from a natural source. Nothing else matters until there is a candidate.

A clinical-stage company needs the layered claim set, the deposits planned against every jurisdiction, the royalty stack modelled, freedom to operate on the platform, and the exclusivity clock mapped alongside the patent term.

A commercial biologics business needs all of that plus term restoration elections, listing decisions, the biosimilar litigation timetable, and a portfolio pruned against the marketed products.

A synthetic biology or industrial biotechnology business needs the detectability assessment that decides patent versus secret, the open source parts analysis, biosafety and dual use compliance, and environmental release documentation.

Review annually, and on six triggers: a new collaboration, a new inbound licence, a publication by a collaborator, a candidate selection, a change in the regulatory pathway, and any competitor filing in the same sequence space.

A Closing Note

Biotechnology intellectual property has narrowed considerably in the last fifteen years, and the narrowing has been doctrinal rather than legislative.

Eligibility took the natural products and the correlations. Enablement, after Amgen, took the broad functional genus. Written description had already taken the antibody claim defined only by its target. What remains is narrower, more structural, and more closely tied to what was actually made and tested.

The correct response is not to mourn the broad claim. It is to file layered claim sets, claim structurally, build the data, plan the deposits, and treat the regulatory exclusivity as a first-class part of the position rather than as something the regulatory department handles.

And it is to take the contractual layer as seriously as the doctrinal one. In this field, more programmes are constrained by a material transfer agreement signed by a postdoctoral researcher, a platform licence with a reach-through, or a publication that preceded a filing, than by any question of claim scope.

Those are all preventable with a calendar and a review habit, which makes them the highest-value work available — and the least likely to be requested.

Enforcement and Defence

Biotechnology infringement is proved by analysis, and the difficulty is access.

Composition claims are the easiest to enforce, because the accused product can be sequenced or characterised and compared to the claim elements directly.

Method of making claims are harder, because the process happens inside a facility. 35 U.S.C. § 271(g) reaches importation of a product made abroad by a patented process, which is the principal route where manufacture is offshore.

Method of treatment claims turn on inducement, since the direct infringer is the physician or the patient. Under 35 U.S.C. § 271(b) the question is whether the label and the marketing instruct the infringing use, and Global-Tech Appliances, Inc. v. SEB S.A., 563 U.S. 754 (2011), requires knowledge of the patent and of the infringement. Skinny labelling — carving out a patented indication — is the standard defensive response, and its adequacy has been litigated repeatedly.

The safe harbour is the first defence in most pre-approval disputes, and its scope is the recurring fight.

Validity attacks concentrate on section 112, and after Amgen the enablement challenge to a functional genus is the strongest available in the field.

Inter partes review is available for patents, and its estoppel consequences under 35 U.S.C. § 315(e) should be modelled before filing, particularly where a parallel district court case is running.

And the trade secret case is different in kind. Identification with reasonable particularity is the threshold, the evidence is in the defendant's laboratory, and the practical value of an ex parte seizure under 18 U.S.C. § 1836 is limited where the material is information rather than a physical sample.

A Ninety-Day Programme

Days one to fifteen. Inventory the inbound obligations: every material transfer agreement, platform licence, sponsored research agreement, and funding condition, with reach-throughs, field limits, royalties, and options extracted into one table.

Days fifteen to thirty. Build the royalty stack model against a representative product, and identify any obligation that makes the programme uneconomic before it becomes an obligation that makes the programme uneconomic.

Days thirty to forty-five. Reconcile the publication calendar with the filing calendar across every collaborator, and adopt a standing rule that no submission, poster, preprint, or presentation precedes a priority filing.

Days forty-five to sixty. Audit the claim sets against the Amgen standard: which claims are functionally defined, what data supports them, and what structural fallbacks exist. Add intermediate claims through continuation where the family is still open.

Days sixty to seventy-five. Map the deposit obligations by jurisdiction against the family's filing dates, and confirm accession numbers, maintenance, and viability records for every deposit already made.

Days seventy-five to ninety. Build the provenance file for every biological material in the programme, and run sequence-level freedom to operate on the lead candidate and the platform stack.

Then review annually, with the inbound obligation table, the publication calendar, and the deposit schedule as the standing items — and the freedom to operate refresh at every milestone.

What Clients Actually Ask

"Can we patent the sequence?" Not the naturally occurring one after Myriad. The engineered construct, the codon-optimised version, the fusion, the vector, the host, and the method of use are all available, and a programme that files only on the natural sequence has no position at all.

"How broad can our antibody claim be?" As broad as the structural data supports. A claim to everything that binds the epitope and blocks the receptor will not survive Amgen, and telling founders this early is considerably kinder than telling them at the second financing.

"Do we need to deposit?" If a skilled artisan could not reproduce the material from the specification, yes — and the deadline in some jurisdictions is the filing date, not the grant date, so the question has to be asked before the priority application goes in.

"Our professor wants to publish next month." File first. The domestic grace period will not save the foreign family, and this is the most common single loss of rights in the field.

"What did we sign for that cell line?" Find the material transfer agreement. There is usually one, it usually has a reach-through, and it is usually in an inbox rather than in a contracts system.

"Is the safe harbour enough?" For development and regulatory submission work, generally yes under 35 U.S.C. § 271(e)(1). For commercial manufacture, no.

"What is our biggest exposure?" Almost always an inbound obligation nobody catalogued, followed by a functional claim that will not survive its first serious challenge.

Diligence, From Both Sides

A buyer or investor asks eight questions, and a company that can answer them in a week is worth more than one that cannot.

Chain of title. Executed assignments from every inventor, including academic collaborators and contractors, recorded under 35 U.S.C. § 261.

Inventorship. Whether the named inventors match the conception records, and whether any correction under section 256 is needed before the transaction rather than after it.

Inbound obligations. The full table: material transfers, platform licences, sponsored research, government funding, and the royalty stack they produce.

Claim scope against the Amgen standard, with an honest assessment of which claims are likely to survive and which are negotiating positions.

Deposits. Accession numbers, jurisdictions, maintenance status, and viability records.

Provenance. Where the biological material came from and under what permits and consents.

Exclusivity. The regulatory clock alongside the patent term, with any restoration election modelled.

And freedom to operate on the candidate and the platform, with the opinions in the data room rather than described in a summary.

A seller who prepares these eight in advance controls the diligence. A seller who assembles them under a signed term sheet discovers the problems at the point of least leverage — which, in this field, is where most value is lost.

A Note on Working With Scientists

The intellectual property questions in this field are asked of people who did not train to answer them, and the practitioner's effectiveness depends more on how the questions are framed than on doctrinal command.

Ask what was actually made and tested, not what the invention is. The answer identifies the species claims, the written description support, and the data map in a single conversation.

Ask what would surprise a competent person in the field. That is the unexpected results showing, in the language a scientist already uses.

Ask where every material came from. It is a provenance question, an inbound obligation question, and a deposit question at once, and scientists usually know the answer immediately.

Ask what is being submitted, presented, or posted in the next ninety days. This single question prevents the most common loss of rights in biotechnology.

Ask whether a competitor could tell from the product. That is the detectability assessment that decides patent versus secret, and the bench team answers it better than counsel ever could.

And explain the Amgen problem in their terms, which is that a claim covering everything that works has to teach how to make everything that works, and a screening protocol is not teaching. Scientists find that entirely intuitive, and it changes what they bring to the drafting meeting.

Six questions, one meeting, and a materially better application than the one that would otherwise have been drafted from a manuscript.

It is also the meeting that surfaces the inbound obligations, because the person who signed the material transfer agreement is usually sitting in it.

That single fact makes the drafting meeting the most efficient diligence exercise available in this field.

Booking an extra thirty minutes for it costs nothing and reliably surfaces something worth knowing.

It is the cheapest item in this toolkit and, over a portfolio, one of the most consequential.

A Suggested Reading Path

Start with the doctrine in Claiming Life.

Then the practice in Protecting a Biotechnology Invention.

Then the audit in the biotechnology IP checklist.

For the disclosure doctrines, The Bargain of Disclosure and the section 112 compliance checklist.

For eligibility, What Can Actually Be Patented and Overcoming a Section 101 Rejection.

For the chemical analogue, Claiming a Compound and the Chemicals, Materials, and Formulations IP Toolkit.

For the regulatory layer, The Dance Before the Drug and the Life Sciences Patent Toolkit.

For collaboration and technology transfer, the technology transfer checklist and the Patent Licensing and Technology Transfer Toolkit.

For provenance and community obligations, Borrowed Patterns and the Traditional Knowledge and Cultural Expressions Toolkit.

And for the secrecy alternative, the Trade Secret Protection Toolkit.

Primary Authorities

| Authority | Proposition | |---|---| | 35 U.S.C. § 101 | Eligible subject matter | | 35 U.S.C. § 102 | Novelty; grace period; publication risk | | 35 U.S.C. § 103 | Obviousness | | 35 U.S.C. § 112 | Written description; enablement; definiteness | | 35 U.S.C. § 116 | Joint inventors | | 35 U.S.C. § 156 | Patent term restoration | | 35 U.S.C. § 262 | Joint owners may exploit independently | | 35 U.S.C. § 271(e)(1) | Regulatory safe harbour | | 35 U.S.C. § 261 | Assignment and recordation | | 18 U.S.C. § 1839 | Trade secret; reasonable measures | | Association for Molecular Pathology v. Myriad Genetics | Isolated DNA ineligible; cDNA eligible | | Mayo Collaborative Services v. Prometheus Laboratories | Natural correlations plus conventional steps | | Alice Corp. v. CLS Bank International | Two-step eligibility framework | | Amgen Inc. v. Sanofi | Enablement of a functional genus | | In re Wands | Undue experimentation factors | | Diamond v. Chakrabarty | Engineered organisms are eligible | | KSR International v. Teleflex | Obviousness framework | | Graham v. John Deere | Obviousness findings | | Nautilus v. Biosig Instruments | Definiteness | | Kewanee Oil v. Bicron | Trade secret coexists with patent | | Phillips v. AWH Corp. | Claim construction | | Festo v. Shoketsu Kinzoku Kogyo Kabushiki | Prosecution history estoppel | | Budapest Treaty deposit requirements | Deposits satisfying enablement | | WIPO genetic resources treaty (2024) | Disclosure of origin | | Nagoya Protocol access and benefit sharing | Permits and consent | | Biologics reference product exclusivity | Approval-based market protection |

Forms and Templates

The Assignment Agreement Template covers inventor, contractor, and collaborator assignments, and in this field it should be paired with a notebook and data retention policy, because the conception records that establish inventorship also supply the evidence for written description and for any later correction under section 256. The License Agreement Template supplies the structure for platform, research tool, and out-licensing arrangements, where the terms that decide the economics are the field limitation, the reach-through royalty, the improvement grant-back, and the diligence obligations. The Portfolio Inventory Template adapts into a combined register of patents, deposits with accession numbers and maintenance dates, inbound licences with their royalty stack, material transfer obligations, and exclusivity clocks. Beyond those, keep four records: a provenance file per biological material; a publication and filing calendar reconciled across every collaborator; a deposit deadline schedule by jurisdiction; and a royalty stack model refreshed at each in-licence.

Related Toolkits and Checklists

The Chemicals, Materials, and Formulations IP Toolkit applies the same scope doctrines to structures and ranges. The Life Sciences Patent Toolkit carries the regulatory exclusivity and litigation timetable. The Patent Licensing and Technology Transfer Toolkit covers the university and platform arrangements this field runs on. The Traditional Knowledge and Cultural Expressions Toolkit covers the provenance and community consent obligations, and the Trade Secret Protection Toolkit covers the alternative route for undetectable process knowledge.